Evidence map›Paper›PMID 39883059›Full record

ArticleMolecular cancer research : MCR2025

Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma.

Warren Phipps, Bhavneet Bhinder, Andrea Towlerton, Peter Mooka, James Kafeero, Matt Fitzgibbon, Olivier Elemento, Ethel Cesarman

Abstract read
In one paragraph

Article in Molecular cancer research : MCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Spatial Profiling Shows That Lymphatic Endothelial Cells Form the Core of Kaposi Sarcoma (KS).Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Warren PhippsFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-4409-3221
Bhavneet BhinderWeill Cornell Medicine, New York, New York.ORCID 0000-0001-6685-8761
Andrea TowlertonFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-7472-789X
Peter MookaUganda Cancer Institute-Fred Hutch Collaboration, Kampala, Uganda.ORCID 0009-0009-3953-090X
James KafeeroUganda Cancer Institute-Fred Hutch Collaboration, Kampala, Uganda.ORCID 0009-0003-1481-2077
Matt FitzgibbonFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0008-7557-0442
Olivier ElementoWeill Cornell Medicine, New York, New York.ORCID 0000-0002-8061-9617
Ethel CesarmanWeill Cornell Medicine, New York, New York.ORCID 0000-0003-3303-6299

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Consortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7M
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell LevelR01CA239287 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHIPPS, WARREN, WARREN, EDUS HOUSTON · 2019 to 2023
$3.3M
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in AfricaR01CA217138 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHIPPS, WARREN, WARREN, EDUS HOUSTON · 2017 to 2021
$2.8M
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to TreatmentK23CA150931 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHIPPS, WARREN · 2011 to 2015
$714k
Defining the Cellular Oncogenome of Kaposi SarcomaR21CA206851 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CESARMAN, ETHEL, PHIPPS, WARREN · 2017 to 2018
$394k
NCI NIH HHS K23 CA150931NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA217138NCI NIH HHS R01 CA239287NCI NIH HHS R21 CA206851NCI NIH HHS UM1 CA121947
6 · The paper itself

Abstract

Kaposi sarcoma is a frequently aggressive malignancy caused by Kaposi sarcoma herpesvirus. People with immunodeficiencies, including human immunodeficiency virus (HIV), are at increased risk for developing Kaposi sarcoma, but our understanding of the contributions of the cellular genome to Kaposi sarcoma pathogenesis remains limited. To determine if there are cellular genetic alterations in Kaposi sarcoma that might provide biological or therapeutic insights, we performed whole-exome sequencing on 78 Kaposi sarcoma tumors and matched normal control skin from 59 adults with Kaposi sarcoma (46 with HIV-associated Kaposi sarcoma and 13 with HIV-negative Kaposi sarcoma) receiving treatment at the Uganda Cancer Institute in Kampala, Uganda. We found a very low mutational burden in all but one specimen (median = 11 mutations), which is the lowest number of mutations among all 33 tumor types in The Cancer Genome Atlas. No recurrent mutations were seen, and the most commonly affected oncogenic pathway was RTK/RAS. Mutational signatures included defective DNA mismatch repair and smoking. There was no evidence suggesting that multiple tumors from the same patient originated from the same original clone. The number of genome copy alterations per genome was higher in tumors from those without HIV infection and in tumors from participants with advanced stage disease, suggesting that lesions that take longer to develop may accumulate more alterations, although the number of alterations remains low compared with other cancers. Implications: Our findings indicate that the pathogenesis of Kaposi sarcoma differs from other malignancies and that the primary driver of carcinogenesis is Kaposi sarcoma-associated herpesvirus infection and expression of viral oncogenes, rather than clonal oncogenic transformation.

Indexed as

ExomeExome SequencingSarcoma, KaposiAdultAgedFemaleGenomicsHumansMaleMiddle AgedMutation

Identifiers

PMID39883059
PMCPMC12048277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.